Early Growth Hormone Treatment Enhances Growth and Nutritional Status in Silver-Russell Syndrome
Authors' conclusion
In prepubertal SRS children, the first 2 years of standard-dose rGH therapy significantly enhance both height and nutritional status. Early initiation of treatment, before the age of 4 years, further optimizes height gain.
Study context
- Population
- Prepubertal children with molecularly proven Silver-Russell syndrome (SRS) during the first 2 years of recombinant growth hormone (rGH) therapy; mean age at rGH initiation 3.7 (1.4–10.3) years
- Participants
- 77 children
- Outcome
- Growth and nutritional status (short-term effects of rGH therapy)
- Follow-up
- First 2 years of rGH therapy
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
- Mean height gain after 1 year
- 0.8 standard deviation score (SDS)
- Mean height gain after 2 years
- 1.3 SDS
- Mean ideal weight for height (WfH) at rGH initiation
- 81%
- Mean WfH after 1 year (P < .001)
- 84%
- Mean WfH after 2 years (P < .001)
- 86%
- Proportion with WfH <75% at rGH initiation
- 22.1%
- Proportion with WfH <75% after 2 years
- 7.8%
Observational data: associations, not effects.
Further findings
Height gain after 2 years by age at rGH start (before vs not before age 4 years)
- Starting rGH before age 4 years associated with greater height increase after 2 years (P = .012)
- 1.5 vs 1.1 SDS
Original publication
Early Growth Hormone Treatment Enhances Growth and Nutritional Status in Silver-Russell Syndrome. J Clin Endocrinol Metab. Published 19 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →